Journal of Analytical Toxicology 2009-01-01

Screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry.

Youwen You, Cornelius E Uboh, Lawrence R Soma, Fuyu Guan, Xiaoqing Li, Jeffrey A Rudy, Jinwen Chen

Index: J. Anal. Toxicol. 33(1) , 41-50, (2009)

Full Text: HTML

Abstract

A sensitive liquid chromatographic-tandem mass spectrometric method was developed and validated for screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma. Analytes were recovered from plasma by liquid-liquid extraction followed by separation in a reversed-phase column and identification by mass spectrometry with selected reaction monitoring in negative electrospray ionization mode. Extraction recovery for both analytes was >80%. Limits of detection, quantification, and confirmation for both analytes were 0.01 microg/mL (S/N>or= 3), 0.05 microg/mL, and 0.05 microg/mL, respectively. The assay with d9-labeled phenylbutazone as internal standard (IS) was linear over a range of 0.05-20 microg/mL (r2>0.995). Intra- and interday precision in terms of coefficient of variation was less than 15%. Intra- and interday accuracy (bias%) was within 80-120%. Hemolysis of red blood cells decreased analyte signal intensity but did not affect quantification results because an isotope-labeled IS was used. Analytes were stable in plasma for 24 h at room temperature, 9 days at 4 degrees C, and 45 days at -20 degrees C and -70 degrees C. The method was successfully used in screening, quantification, and confirmation of phenylbutazone in post-competition plasma samples obtained from racehorses. The method is simple, rapid, and reliably reproducible.


Related Compounds

Related Articles:

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I.

1986-07-01

[Adverse Drug React. Acute Poisoning Rev. 5(2) , 97-136, (1986)]

Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part II.

1986-10-01

[Adverse Drug React. Acute Poisoning Rev. 5(3) , 181-96, (1986)]

Disposition and tolerance of suxibuzone in horses.

1999-09-01

[Equine Vet. J. 31(5) , 411-6, (1999)]

Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys.

2001-05-01

[Am. J. Vet. Res. 62(5) , 673-5, (2001)]

Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6 A resolution.

2004-11-23

[Biochemistry 43(46) , 14577-83, (2004)]

More Articles...